Literature DB >> 6440605

Physiological variables and mortality in patients with various categories of chronic respiratory disease.

J M Bishop, K W Cross.   

Abstract

As an introduction to a prospective study on the complex non-invasive estimation of pulmonary arterial pressure, the mortality experience of 834 patients with chronic respiratory disease was analysed historically. In patients with chronic obstructive lung disease, chronic fibrosing alveolitis and pulmonary tuberculosis, the relationships between mortality and values of ten physiological variables were examined. The most important variable as regards mortality in chronic obstructive lung disease was FEV1.0; after controlling for FEV1.0, pulmonary arterial pressure, arterial oxygen and carbon dioxide pressures were all strongly related to mortality. By contrast, in fibrosing alveolitis, values of FEV1.0 had little relation to mortality, and pulmonary arterial pressure was the most important variable, followed by FVC and FEV/VC. In patients with tuberculosis, arterial oxygen and pulmonary arterial pressure had the strongest relationship with mortality. Pulmonary arterial pressure was therefore strongly related to mortality in all three conditions; FEV1.0 had its highest predictive power in chronic obstructive lung disease and arterial oxygen saturation in tuberculosis. In chronic obstructive lung disease, pulmonary arterial pressure had a stronger influence in relation to mortality of younger than of older patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6440605

Source DB:  PubMed          Journal:  Bull Eur Physiopathol Respir        ISSN: 0395-3890


  15 in total

Review 1.  Chronic cor pulmonale.

Authors:  Emmanuel Weitzenblum
Journal:  Heart       Date:  2003-02       Impact factor: 5.994

2.  Early experience of heart-lung transplantation.

Authors:  R L Smyth; T W Higenbottam; J P Scott; J P McGoldrick; B Whitehead; P Helms; M de Leval; J Wallwork
Journal:  Arch Dis Child       Date:  1989-09       Impact factor: 3.791

Review 3.  Should patients have right heart catheterization prior to long-term oxygen treatment?

Authors:  E Weitzenblum; M Apprill; M Ehrhart; M Oswald
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 4.  Can pulmonary vasodilators improve survival in cor pulmonale due to hypoxic chronic bronchitis and emphysema?

Authors:  K F Whyte; D C Flenley
Journal:  Thorax       Date:  1988-01       Impact factor: 9.139

5.  Novel Therapeutic Approaches of Pulmonary Arterial Hypertension.

Authors:  Sanjay Tyagi; Vishal Batra
Journal:  Int J Angiol       Date:  2019-07-12

Review 6.  The role of imaging in pulmonary hypertension.

Authors:  Meenal Sharma; Andrew T Burns; Kelvin Yap; David L Prior
Journal:  Cardiovasc Diagn Ther       Date:  2021-06

Review 7.  Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update.

Authors:  Denis E O'Donnell; Shaw Aaron; Jean Bourbeau; Paul Hernandez; Darcy D Marciniuk; Meyer Balter; Gordon Ford; Andre Gervais; Rogers Goldstein; Rick Hodder; Alan Kaplan; Sean Keenan; Yves Lacasse; Francois Maltais; Jeremy Road; Graeme Rocker; Don Sin; Tasmin Sinuff; Nha Voduc
Journal:  Can Respir J       Date:  2007-09       Impact factor: 2.409

8.  Detection of pulmonary hypertension by Doppler echocardiography of the inferior vena cava in chronic airflow obstruction.

Authors:  J P Laaban; B Diebold; M Lafay; J Rochemaure; P Peronneau
Journal:  Thorax       Date:  1989-05       Impact factor: 9.139

Review 9.  [Right heart failure and cor pulmonale].

Authors:  M Leschke; A Wädlich
Journal:  Internist (Berl)       Date:  2007-09       Impact factor: 0.743

10.  Validity of the surface electrocardiogram criteria for right ventricular hypertrophy: the MESA-RV Study (Multi-Ethnic Study of Atherosclerosis-Right Ventricle).

Authors:  Isaac R Whitman; Vickas V Patel; Elsayed Z Soliman; David A Bluemke; Amy Praestgaard; Aditya Jain; David Herrington; Joao A C Lima; Steven M Kawut
Journal:  J Am Coll Cardiol       Date:  2013-09-28       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.